Adam Feuerstein details 12 winners and losers from the ASCO oncology conference: The winners...
Adam Feuerstein details 12 winners and losers from the ASCO oncology conference: The winners include Bristol-Myers (BMY) for its anti-PD-1 immunotherapy, which "has blockbuster potential across several solid tumors." Onyx (ONXX) is both, as Carfilzomib is a "real multiple myeloma drug" but investors are pessimistic about its FDA chances.
From other sites
Video at CNBC.com (Sep 9, 2015)
Video at CNBC.com (Aug 21, 2015)
at CNBC.com (Jun 1, 2015)
Video at CNBC.com (May 26, 2015)
Video at CNBC.com (Mar 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs